MLTX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 6.32%, SMA50 14.08%, SMA200 -42.56%). The stock’s 14-day RSI is 58.23 (neutral), while the ATR of 1.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -71.82% below its high and over 197.14% above its low. Average 10-day trading volume of 1.21 million shares is slightly above the 3-month average of 1.02 million, indicating heightened recent market interest.

MoonLake Immunotherapeutics has 63.50 million shares outstanding. The public float is 24.16 million shares, elevated short interest at 21.68% of float. This equals 6.13 million shares. The short ratio is 12.16 days. Institutional investors hold 84.42% of the float. Insiders own 10.41%. Santos da Silva Jorge holds 2.92 million shares, Reich Kristian has 2.82 million shares and Chen Bihua has 1.99 million shares. Over the past six months, insider transactions show net selling. They sold 670.28 thousand shares across 12 transactions.

MoonLake Immunotherapeutics last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.01. This means the shares are trading above this model’s fair value.

MoonLake Immunotherapeutics (NASDAQ:MLTX) closed at $22.16 USD, gaining $2.95 (15.36%) from the previous close of $19.21. The stock is currently mid-range between its 52-week high and low $5.95 and $62.75. With a market capitalization of about $1.63 billion, MoonLake Immunotherapeutics is classified as a small-cap and shows market-like volatility (beta ~1.04). Key stats such as the average daily volume over the past year has been around 1.04 million shares, trading with heavier-than-usual volume. Headquartered in Zug, None, MoonLake Immunotherapeutics operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jorge Santos da Silva, the company employs approximately 100 people and listed since October 20, 2020. MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies.

MoonLake Immunotherapeutics generated EPS of -$3.53 over the past year. Five-year average earnings growth is -256.78%. Wall Street analysts project EPS growth of 11.92% annually over the next five years. The latest quarter delivered EPS of -$0.98. The next quarter is forecast at -$0.89. Next year's EPS is expected at -$42.85. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 20 Buy ratings, 5 Hold ratings, 2 Sell rating and 0 Strong Sell ratings. Price targets range from $85.00 to $5.00. The high target offers 283.57% upside. The low target suggests -77.44% downside. The mean target is $30.57. This offers 37.95% upside. MoonLake Immunotherapeutics earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 11, 2026, missed forecasts by 7.69%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 35.85% in February 26, 2025.

MoonLake Immunotherapeutics trades at a P/E ratio of -5.68, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 6.19 trading at moderately above to book value. The P/FCF stands at -7.24, also above market averages.

Our AI price prediction model suggests that MoonLake Immunotherapeutics stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.3%, with price expected at $22.67 by July 06, 2026, within a range of $21.84 to $23.51 3-Month Outlook: Projected fall of -42.6%, reaching $12.72 by September 16, 2026, with a range of $6.76 to $13.54. 1-Year Outlook: Projected loss of -74.86%, with price at $5.57 by June 22, 2027, within a range of $0.32 to $10.12.

MoonLake Immunotherapeutics (NASDAQ:MLTX) shares are up 23.9% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows MoonLake Immunotherapeutics trading at a premium to the broader market with a P/E of -5.68. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $48.04, suggesting 116.79% upside. Our AI forecast model points to short-term strength (2.3% over two weeks), a medium-term fall (-42.6% over three months), and a longer-term loss (-74.86% over one year), with expected trading ranges indicating moderate volatility.